Pfizer needs to prove it's a growth story

Pfizer needs to show the market that it is indeed a growth story if it hopes to win back investors

With shares of Pfizer trading near a 52-week low in the wake of its deal with Mylan, the pharma will need to show the market that it is indeed a growth story if it hopes to win back disenchanted investors.

Pfizer Inc. (NYSE:PFE) shares were hammered after the company released a flurry of news Monday that included a complicated deal with Mylan N.V.

Read the full 627 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE